Search Icon
Search Icon
close-panel

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Get Notifications

Sign up to receive email updates from Charlotte Lozier Institute.

This field is for validation purposes and should be left unchanged.

Become A Defender of Life

Your donation helps us continue to provide world-class research in defense of life.

DONATE

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Life & the LawAbortion Drugs Issues in Law & Medicine

A Critical Analysis of the FDA’s 2021 Mifepristone REMS Modification Rationale Review

Abstract

Mifepristone was first approved in 2000 in conjunction with misoprostol to induce abortion, and both its initial approval and subsequent regulation have been controversial. In 2021, the Food and Drug Administration (FDA) undertook a full review of the mifepristone Risk Evaluation and Mitigation Strategy (REMS) program, with the aim of assessing the necessity of each of the three Elements to Assure Safe Use (ETASUs) present in the mifepristone REMS, including ETASU C, the “in-person dispensing requirement.” Following this review, the FDA concluded that ETASU C could be safely removed and that mifepristone could be safely dispensed outside of the previously approved settings. This paper seeks to critically analyze the 2021 REMS Review, as well as the studies cited therein to determine whether the evidence presented by the FDA sufficiently substantiated this decision. Factors that render the cited studies non-replicative of real-world, non-study conditions and therefore unable to be generalized to these contexts are highlighted. Differential treatment of stakeholder input and limitations of abortion complication reporting systems are also discussed. The clinical implications of the FDA’s decision to remove ETASU C are noted, followed by several actionable recommendations to the FDA.

Read Press Release

Read Complete Article

Latest Posts

November 16, 2026 Two cupped hands holding a small model of a human fetus. The new legal landscape after the abortion ballot initiatives November 9, 2026 Minimalist illustration of a small, flat-roofed building serving as a United States abortion center, featuring two windows and a central door. Fact Sheet: Gestational Breakdown of Brick-and-Mortar Abortion Centers in The United States October 6, 2026 Ultrasound image showing the side profile of a human baby Inside The Government Decision That Opened Up Abortion Pill Floodgates

You Might Also Be Interested In

Two cupped hands holding a small model of a human fetus.

The new legal landscape after the abortion ballot initiatives

November 16, 2026
Minimalist illustration of a small, flat-roofed building serving as a United States abortion center, featuring two windows and a central door.

Fact Sheet: Gestational Breakdown of Brick-and-Mortar Abortion Centers in The United States

charlotte-lozier-institute Charlotte Lozier Institute
November 9, 2026
A sign for the FDA featuring the agency’s logo and circular seals in front of a brick government building, where clinical guidance for mifepristone REMS is often determined.

Unintended Consequences of the FDA’s 2021-2023 Risk Evaluation and Mitigation Strategy (REMS) Changes to Mifepristone

Become A Defender of Life

Your donation helps us continue to provide
world-class research in defense of life.

BECOME A PARTNER
cta-image